Literature DB >> 856428

Metabolic balance studies in patients with Paget's disease receiving salmon calcitonin over long periods.

D G Oreopoulos, H Husdan, J Harrison, H E Meema, K G McNeill, T M Murray, R Ogilvie, A Rapoport.   

Abstract

Metabolic balance and calcium kinetic studies were performed in four patients with Paget's disease before treatment with salmon calcitonin and during the early and late stages of the treatment, which lasted 9 to 19 months, A significant decrease in bone turnover and 24-hour urine hydroxyproline and serum alkaline phosphatase values was observed in all patients. In contrast, the calcium, phosphorus and magnesium balances did not change significantly. In agreement with this, the partial body calcium, measured by in vivo neutron activation analysis, did not change. Intestinal calcium absorption increased initially, but returned to baseline levels 9 to 19 months after the study began. During the initial period there was a small, significant, but transient decrease in tubular reabsorption of phosphorus; this was accompanied by a significant decrease in serum phosphorus values--probably a direct effect of calcitonin rather than evidence of secondary hyperparathyroidism. Administration of salmon calcitonin to patients with Paget's disease decreases bone turnover without affecting calcium and phosphorus balances.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 856428      PMCID: PMC1879370     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  16 in total

1.  A METHOD FOR DETERMINATION OF BONE-SALT CONTENT OF CORTICAL BONE.

Authors:  H E MEEMA; C K HARRIS; R E PORRETT
Journal:  Radiology       Date:  1964-06       Impact factor: 11.105

2.  In vivo neutron activation analysis for calcium in man.

Authors:  K G McNeill; B J Thomas; W C Sturtridge; J E Harrison
Journal:  J Nucl Med       Date:  1973-07       Impact factor: 10.057

3.  Human calcitonin in the treatment of Paget's bone disease.

Authors:  N J Woodhouse; P Bordier; M Fisher; G F Joplin; M Reiner; D N Kalu; G V Foster; I MacIntyre
Journal:  Lancet       Date:  1971-06-05       Impact factor: 79.321

4.  Non-autonomy of hormone secretion in primary hyperparathyroidism.

Authors:  T M Murray; M Peacock; D Powell; J M Monchik; J T Potts
Journal:  Clin Endocrinol (Oxf)       Date:  1972-07       Impact factor: 3.478

5.  Calcium kinetic studies in patients with malabsorption syndrome.

Authors:  J E Harrison; A J Hitchman; J M Finlay; K G McNeill
Journal:  Gastroenterology       Date:  1969-04       Impact factor: 22.682

6.  Metabolic effects of synthetic salmon calcitonin in Paget's disease of bone.

Authors:  A Avramides; R K Baker; S Wallach
Journal:  Metabolism       Date:  1974-11       Impact factor: 8.694

7.  An evaluation of isotopic calcium absorption tests.

Authors:  J E Harrison; K G McNeill; D R Wilson; D G Oreopoulos; A Krondl; J M Finlay
Journal:  Clin Biochem       Date:  1973-12       Impact factor: 3.281

8.  Effects of calcitonin in Paget's disease and polyostotic fibrous dysplasia.

Authors:  N H Bell; S Avery; C C Johnston
Journal:  J Clin Endocrinol Metab       Date:  1970-09       Impact factor: 5.958

9.  The immunochemical specificity of antisera to bovine parathyroid hormone: an approach to region-specific radioimmunoassay.

Authors:  T M Murray; H T Keutmann
Journal:  J Endocrinol       Date:  1973-03       Impact factor: 4.286

10.  The clinical and metabolic effects of porcine calcitonin on Paget's disease of bone.

Authors:  F Shai; R K Baker; S Wallach
Journal:  J Clin Invest       Date:  1971-09       Impact factor: 14.808

View more
  2 in total

1.  Long-term measurement of skeletal and lean body mass in Paget's disease of bone treated with synthetic human calcitonin.

Authors:  T J Spinks; G F Joplin; I M Evans; J Pennock; F H Doyle; A S Ranicar
Journal:  Calcif Tissue Int       Date:  1982-09       Impact factor: 4.333

2.  Long-term treatment of Paget's disease of bone with salmon calcitonin.

Authors:  W C Sturtridge; J E Harrison; D R Wilson
Journal:  Can Med Assoc J       Date:  1977-11-05       Impact factor: 8.262

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.